Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Alfonso Martín-Carnicero

7PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

Sort by Publication Date:
|Jul 01, 2026
Optimized chemotherapy sequence for metastatic pancreatic ductal adenocarcinoma patients: FOLFIRINOX followed by Gemcitabine plus nab-paclitaxel.

|Feb 12, 2026
Predictive value of natural killer (NK) cells in bone marrow for relapse in diffuse large B cell lymphoma: integrating antibody-dependent cell-mediated cytotoxicity (ADCC)-based immunotherapy.

Sofía Rincón-López, Johelys Atencio-Matos, Olalla Pereda-Sainz

|Jun 27, 2024
Detection of Tumor-Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes.

Francisco Corzana, Alicia Asín, Ander Eguskiza

|Mar 13, 2024
Expression of Mitochondrial Long Non-Coding RNAs, MDL1 and MDL1AS, Are Good Prognostic and/or Diagnostic Biomarkers for Several Cancers, Including Colorectal Cancer.

Pablo Garrido, Adrián Casas-Benito, Ignacio M Larrayoz

|Sep 09, 2023
Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma.

Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Guillermo Prado-Vázquez

|Jan 08, 2023
Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma.

Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Guillermo Prado-Vázquez

Pageof 2

Frequent Collaborators

4 joint publications

Alfredo Martínez

2 joint publications

Lucía Trilla-Fuertes

2 joint publications

Margarita Majem

2 joint publications

Elisabeth Pérez-Ruiz

2 joint publications

Joaquín Fra

2 joint publications

Ricardo Ramos-Ruiz

2 joint publications

Juan Ángel Fresno Vara

1 joint publications

Enrique Ramalle-Gomara

1 joint publications

María González-Cao

1 joint publications

Angelo Gámez-Pozo

Frequent Collaborators

4 joint publications

Alfredo Martínez

2 joint publications

Lucía Trilla-Fuertes

2 joint publications

Margarita Majem

2 joint publications

Elisabeth Pérez-Ruiz